MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
51.87
-0.07
-0.13%
After Hours: 51.87 0 0.00% 18:18 07/13 EDT
OPEN
51.07
PREV CLOSE
51.94
HIGH
52.00
LOW
50.54
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
55.67
52 WEEK LOW
25.17
MARKET CAP
8.65B
P/E (TTM)
57.68
1D
5D
1M
3M
1Y
5Y
1D
Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)
TipRanks · 7h ago
Alkermes Price Target Raised to $62.00/Share From $61.00 by Needham
Dow Jones · 7h ago
Alkermes Is Maintained at Buy by Needham
Dow Jones · 7h ago
Needham Maintains Buy on Alkermes, Raises Price Target to $62
Benzinga · 8h ago
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study
Benzinga · 8h ago
American Express, Biogen upgraded: Wall Street’s top analyst calls
TipRanks · 10h ago
Thome Reiterates Buy on Encouraging Alixorexton Data and Reduced Oxybate Competition, Lifting Price Target to $57
TipRanks · 10h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Conmed (CNMD) and Alkermes (ALKS)
TipRanks · 10h ago
More
About ALKS
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.